Replies to post #659058 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The first CTLA-4 inhibitor, ipilimumab, was approved by the FDA in 2011. The first PD-1 inhibitors, pembrolizumab and nivolumab, were approved in 2014

The foundational research leading to the blockbuster PD1 drugs that we have today preceded those first approvals by decades beginning in the 1980s and 1990s. I think it’s important to appreciate that PD1 blockade technology didn’t come to fruition overnight.

PD-1 was first described in the early 1990s. The first to get approved was keytruda that was developed around 2006-7 (see) and entered the clinic 2011 for the first P1. It was FDA approved in 2014.(see)

DC's were first described in early 1970's. ATL based DC therapies were some of the first to be investigated in the mid 1990s. The first clinical trial for -L was sometime prior to 2001 (asserted by NWBO in their initial S1).

In short the DC-L timeline started about a decade earlier and is not a decade later.

To imply in any way the NWBO timeline is rational is absurd.